Literature DB >> 18398975

Similar efficacy of lopinavir/ritonavir-containing regimens among clades B and F HIV-1-Infected individuals in Brazil.

Ricardo Sobhie Diaz, Lucy Vasconcelos, Ricardo L Hayden, Simone Tenore, Gilberto Turcato, Ricardo Palácios, Maria C Sucupira.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18398975     DOI： 10.1097/qai.0b013e31815b0d48

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  3 in total

1.  Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.

Authors:  Constance Delaugerre; Philippe Flandre; Marie Laure Chaix; Jade Ghosn; François Raffi; Pierre Dellamonica; H Jaeger; D Shürmann; Isabelle Cohen-Codar; Philippe Ngo Van; Michael Norton; Anne-Marie Taburet; Jean-François Delfraissy; Christine Rouzioux
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

2.  The Influence of HIV-1 Subtype in the Response to Therapeutic Dendritic Cell Vaccine.

Authors:  Valéria Ferreira; Patrícia Moura; Sergio Crovella; Ricardo Sobhie Diaz; Adauto Castelo Filho; Ricardo Ximenes; Luiz Cláudio Arraes
Journal:  Open AIDS J       Date:  2012-12-14

3.  Comparable long-term efficacy of Lopinavir/Ritonavir and similar drug-resistance profiles in different HIV-1 subtypes.

Authors:  Zehava Grossman; Jonathan M Schapiro; Itzchak Levy; Daniel Elbirt; Michal Chowers; Klaris Riesenberg; Karen Olstein-Pops; Eduardo Shahar; Valery Istomin; Ilan Asher; Bat-Sheva Gottessman; Yonat Shemer; Hila Elinav; Gamal Hassoun; Shira Rosenberg; Diana Averbuch; Keren Machleb-Guri; Zipi Kra-Oz; Sara Radian-Sade; Hagit Rudich; Daniela Ram; Shlomo Maayan; Nancy Agmon-Levin; Zev Sthoeger
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.